CliffBio
small molecule

MONTELUKAST SODIUM

MONTELUKAST SODIUM

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameMONTELUKAST SODIUM
Active ingredientMONTELUKAST SODIUM
StrengthEQ 10MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2016
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

MONTELUKAST SODIUM patent cliff — loss of exclusivity — | CliffBio